Malignant neoplasm of right kidney, except renal pelvis
ICD-10 C64.1 is a billable code used to indicate a diagnosis of malignant neoplasm of right kidney, except renal pelvis.
C64.1 refers to a malignant neoplasm located in the right kidney, excluding the renal pelvis. This condition is characterized by the uncontrolled growth of abnormal cells in the kidney tissue, which can lead to the formation of tumors. The right kidney is one of two bean-shaped organs responsible for filtering blood, producing urine, and regulating electrolytes. Malignant neoplasms of the kidney can present with various symptoms, including hematuria (blood in urine), flank pain, and unexplained weight loss. Diagnosis typically involves imaging studies such as ultrasound, CT scans, or MRI, followed by a biopsy to confirm malignancy. Staging of kidney cancer is crucial for determining treatment options and prognosis, often classified using the TNM system (Tumor, Node, Metastasis). Surgical management may include nephrectomy (partial or total removal of the kidney), which is the primary treatment for localized tumors. In cases of advanced disease, additional therapies such as targeted therapy, immunotherapy, or chemotherapy may be considered. Accurate coding for C64.1 is essential for proper treatment planning and reimbursement.
Detailed pathology reports, imaging studies, and treatment plans.
Initial diagnosis of renal cell carcinoma, staging workup, and treatment planning.
Ensure accurate staging and documentation of any metastasis.
Operative reports, pre-operative assessments, and post-operative follow-ups.
Nephrectomy for renal tumors, management of complications post-surgery.
Documenting the surgical approach and any complications encountered.
Used for surgical management of localized renal tumors.
Operative report detailing the procedure and findings.
Urologists must document the surgical approach and any complications.
The primary treatment for malignant neoplasm of the right kidney is surgical intervention, typically nephrectomy, depending on the stage and size of the tumor.
